Plasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease: Results of a Cohort Study

Angiology

Volumn 67, Issue 9, 2016, Pages 870-874

  Signorelli, Salvatore Santo ^a   Anzaldi, Massimiliano ^a   Libra, Massimo ^a   Navolanic, Patrick M ^a   Malaponte, Graziella ^a   Mangano, Katia ^a   Quattrocchi, Cinzia ^a   Di Marco, Roberto ^a   Fiore, Valerio ^a   Neri, Sergio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

atherosclerosis; biomarkers; inflammation; peripheral arterial disease

Indexed keywords

BIOLOGICAL MARKER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; L SELECTIN; NEOPTERIN; PADGEM PROTEIN; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; CELL ADHESION MOLECULE; IL6 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

AGED; ANKLE BRACHIAL INDEX; ARTERIAL PRESSURE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; BLOOD; CASE CONTROL STUDY; FEMALE; MALE; MIDDLE AGED;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84987940149     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319716633339     Document Type: Article

References (44)

1. Leng GC, Lee AJ, Fowkes FGR, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996; 25 (6): 172-181.
2. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992; 326 (6): 381-386.
3. McCombs PR, Subramanian S,. The benefit of exercise in intermittent claudication: effects on collateral development, circulatory dynamics and metabolic adaptations. Ann Vasc Surg. 2002; 16 (6): 791-796.
4. Scott-Okafor HR, Silver KK, Parker J, Almy-Albert T, Gardner AW,. Lower extremity strength deficits in peripheral arterial occlusive disease patients with intermittent claudication. Angiology. 2001; 52 (1): 7-14.
5. Ridker PM, Stampfer MJ, Rifai N,. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001; 285 (19): 2481-2485.
6. Libby P, Ridker PM, Maseri A,. Inflammation and atherosclerosis. Circulation. 2002; 105 (9): 1135-1143.
7. Ross R,. Atherosclerosis as an inflammatory disease. N Engl J Med. 1999; 340 (2): 115-126.
8. Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G,. A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemostas. 2007; 5 (9): 1793-1794.
9. Oren H, Erbay AR, Balci M, Cehreli S,. Role of novel biomarkers of inflammation in patients with stable coronary heart disease. Angiology. 2007; 58 (2): 148-155.
10. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006; 166 (13): 1342-1344.
11. Rothenbacher D, Muller-Schulze S, Herder C, Koenig W, Kolb H,. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol. 2006; 26 (1): 194-199.
12. Miller M, Zhan M, Havas S,. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Int Med. 2005; 165 (18): 2058-2060.
13. Margolis KL, Manson JE, Greenland P, et al. Women's Health Initiative Research Group. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med. 2005; 165 (5): 487-488.
14. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Loewe GDO, Fowkes FGR,. Inflammatory, haemostatic and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007; 28 (3): 354-382.
15. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984; 160 (1): 310-316.
16. Tatzber F, Rabi H, Koriska K, et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis. 1991; 89 (2-3): 203-208.
17. Pacileo M, Cirillo P, De Rosa S, et al. The role of neopterin in cardiovascular disease. Monaldi Arch Chest Dis. 2007; 68 (2): 68-73.
18. Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY,. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med. 2005; 37 (1): 61-66.
19. Van der Zee PM, Biro E, Ko Y, et al. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem. 2006; 52 (4): 657-664.
20. Ruotsalainen E, Vauhkonen I, Salmenniemi U, et al. Markers of endothelial dysfunction and low-grade inflammation are associated in the offspring of type 2 diabetic subjects. Atherosclerosis. 2008; 197 (1): 271-277.
21. Kistorp C, Chong AY, Gustafsson F, et al. Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes. Eur J Heart J. 2008; 10 (4): 380-387.
22. Massova L, Kotra LP, Fridman R, Mobashery S,. Matrix metalloproteinase: structures, evolution and diversification. FASEB J. 1998; 12 (12): 1075-1085.
23. Hiatt WR,. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001; 344 (21): 1608-1621.
24. Pearson TA, Blair SN, Daniels SR,. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002; 106 (3): 388-391.
25. Belch JJ, Topol EJ, Agnelli G, et al. Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003; 163 (8): 884-892.
26. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J,. Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg. 2005; 29 (2): 171-176.
27. Loewe GD, Rumley A, Whincup JH, Danish J,. Haemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med. 2002; 2 (4): 429-439.
28. Brevetti G, Piscione F, Silvestro A, et al. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost. 2003; 89 (6): 1058-1063.
29. Unlu Y, Karapolat S, Karaca Y, Kiziltunc A,. Comparison of levels of inflammatory markers and haemostatic factors in the patients with and without peripheral arterial disease. Thromb Res. 2006; 117 (4): 357-364.
30. Signorelli SS, Malaponte G, Libra M, et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med. 2005; 10 (1): 1-6.
31. Barani J, Nilson JA, Mattiason I, Lindblad B, Gootsater A,. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg. 2005; 42 (1): 75-80.
32. McDermott MM, Green D, Greenland P, Liu K, Criqui MH, Chan C,. Relation of levels of haemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol. 2003; 92 (2): 194-199.
33. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Luscher TF,. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med. 2007; 12 (2): 113-122.
34. Nylande M, Kroese A, Stranden E, et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med. 2006; 11 (1): 21-28.
35. Signorelli S, Mazzarino MC, Di Pino L, et al. High circulating levels of cytokines (IL-6 and TNFα), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after treadmill test. Vasc Med. 2003; 8 (1): 15-20.
36. Signorelli SS, Mazzarino MC, Spandidos DA, Malaponte G,. Proinflmmatory circulating molecules in peripheral arterial disease. Int J Mol Med. 2007; 20 (3): 279-286.
37. Nagase H,. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997; 378 (3-4): 151-160.
38. Lijnen HR,. Metalloproteinase in development and progression of vascular disease. Pathophysiol Haemost Thromb. 2003 / 2004; 33 (5-6): 275-281.
39. Saito S, Zempo N, Yamashita A, Takenaka H, Fujioka K, Esato K,. Matrix metalloproteinases expression in atherosclerotic aneurismal disease. Vasc Endovasc Surg. 2002; 36 (1): 1-7.
40. Beaudeaux JL, Giral P, Bruckert E, Bernard M, Foglietti MJ, Chapman MJ,. Serum matrix metalloproteinases-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipdemia. Atherosclerosis. 2003; 169 (1): 139-146.
41. Raffetto JD, Khalil RA, Matrix metalloproteinase and their inhibitors in vascular remodelling and vascular disease. Bioch Pharmacol. 2008; 75 (2): 346-359.
42. Ferroni P, Basili S, Martini F, et al. Serum metalloproteinase 9 levels in patients with coronary heart disease: a novel marker of inflammation. J Investig Med. 2003; 51 (5): 295-300.
43. Ray KK, Cannon CP,. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol. 2004; 15 (6): 673-643.
44. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcome after statin therapy. N Engl J Med. 2005; 352 (1): 20-28.